Advanced Lipid Nanoparticle (LNP) Analysis and RNA Therapy Solutions

Innovative Solutions for Lipid Nanoparticles

RNAnalytics is a pioneer in the development of advanced analytical methods for Lipid Nanoparticles (LNPs), which play a crucial role in RNA therapy. As part of the renowned Austrian incubator Accent and supported by the aws Pre Seed Program, we continuously expand our technologies and innovations.

Our main project is the development of the GeneVecto Analyzer, a one-step method that combines Taylor Dispersion Analysis (TDA) and Capillary Electrophoresis (CE). This technology enables precise measurement of LNP size distribution and RNA encapsulation efficiency, significantly improving the efficiency and cost-effectiveness of analysis processes. With the GeneVecto Analyzer, we aim to reduce LNP characterization costs by up to 70% and save 50% of the time.

Additionally, we are developing a software platform for LNP characterization that seamlessly integrates with the GeneVecto Analyzer. The platform enables automated data collection, analysis, and visualization, accelerating result interpretation and enhancing analysis accuracy. Users can monitor key parameters such as LNP size, stability, and encapsulation efficiency in real-time.

In the future, we plan to expand our methodology to include not only CE but also HPLC and mass spectrometry. With our sample preparation and LNP component separation kit, we enable comprehensive analysis of LNP structures and compositions. Furthermore, we are developing cell-based assays to assess the potency and tissue specificity of LNPs, which are crucial for therapeutic applications.

This strategic expansion will allow us to meet a broader range of analysis requirements in the pharmaceutical and biotech industries and to further develop our platform for diverse applications.

News

September 2024 - In September, we focused on preparing to onboard an apprentice through the "Women in Technology" program, marking an important milestone in our commitment to fostering diversity in tech. We're excited to embark on this path to develop new talent. Another significant achievement: the development of our Python pipeline for automated analysis of LNP size, size distribution, and loading efficiency was successfully completed. This will enable even faster and more precise data analysis. Additionally, we completed recruitment for two Bioinformatics Master’s theses, and we look forward to working with the new students joining us in 2025.

August 2024 - August was a month of progress at RNAnalytics. We achieved significant optimizations in our analytical methods, particularly with specialized coatings for improved LNP separation. These advancements will make our LNP characterization even more precise and efficient. We also submitted multiple grant applications to secure funding for ongoing R&D projects and future innovations. Another milestone: we concluded four internships, providing students with valuable insights into our processes. Recruitment for a Master’s thesis in CE has also begun, with the project set to start in Q1 2025.

July 2024 - A busy month at RNAnalytics: We expanded our team with four temporary staff members to support our method optimizations. Work on TDA improvements is in full swing. A key milestone was reached: we can now manufacture LNPs in-house, saving costs and increasing project flexibility. We successfully transitioned our accounting to Dynamics 365 and set up SOPs, forms, and logbooks for our equipment. Additionally, we implemented an Access-based chemical database to manage our inventory efficiently. We also began applying for further funding to support our ongoing research projects.

June 2024 - June was a month of networking and team-building efforts. We participated in Vienna Up and aws Connect Day, where we made valuable connections. In the lab, we procured, installed, and tested essential equipment like a centrifuge, vortex mixer, ultrasonic bath, syringe pump, and pH meter. We also installed a new air conditioning system to ensure optimal working conditions. We laid the foundation of our QMS and established our first academic collaborations, pushing our research efforts forward.

May 2024 - A productive month: We completed lab renovations, including the installation and maintenance of our CE system and its software. We placed orders for necessary reagents and began DoE for our next research projects. Simultaneously, we updated our pitch deck and showcased our work at the "Long Night of Research", giving us a great opportunity to present RNAnalytics to the public.

April 2024 - April was productive for RNAnalytics. We participated in Analytica in Munich from April 9-12, an excellent opportunity to connect with industry experts and present our latest products and services. We also increased our visibility and forged new business contacts. Back at the Tulln lab, we completed renovations and installed new software for our analysis devices, improving the efficiency of our R&D processes. We successfully recruited new interns who will bring fresh ideas and energy to our team.

March 2024 - A busy month for RNAnalytics: We attended the RNA Leaders Europe Congress in Basel, Switzerland, from March 13-14, an ideal event for networking and discussing the latest trends in gene therapy. The arrival of our CE system from Korea marked another milestone in our research, playing a key role in LNP analysis. We also interviewed candidates for our internship positions to strengthen our team.

February 2024 - A pivotal month for RNAnalytics: We officially registered as a GmbH, a key step in our company’s formation. Shortly after, we received the keys to our new lab at MakerSpace in Tulln, offering optimal conditions for R&D. We started setting up the lab and installed our first specialized analysis devices, crucial for the quality of our research. At the same time, we expanded our IT infrastructure to optimize processes and boost efficiency.

January 2024 - We are on the verge of moving into our new lab at MakerSpace in Tulln, a modern facility that will support our R&D efforts. Before the move, we made a significant investment in our future by ordering specialized analysis devices.

December 2023 - A key organizational step: We signed the RNAnalytics GmbH shareholder agreement and appointed Viktoria Enkmann as the managing director. We also completed the Accent Bootcamp with Gigi Wang, providing valuable insights and strategies for our growth.

November 2023 - Our vision and commitment to innovation were recognized with the approval of aws Pre Seed funding. This grant provides crucial resources for advancing our LNP analytical methods.

Oktober 2023 - RNAnalytics took a major step by joining the renowned Austrian incubator Accent. At the same time, we began the Accent Bootcamp with Gigi Wang, running until December 2023, aimed at refining our business model and strategy.